Covered recipient · General Payments record
ANGEL R CHINEA
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$196,275.82
300 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $161,295.30 | 70 |
| Consulting Fee | $14,521.00 | 8 |
| Travel and Lodging | $10,177.13 | 18 |
| Food and Beverage | $9,388.14 | 201 |
| Honoraria | $800.00 | 1 |
| Education | $94.25 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $51,705.90 | 73 |
| EMD Serono, Inc. | $44,431.93 | 64 |
| GENZYME CORPORATION | $27,657.24 | 29 |
| Genentech USA, Inc. | $22,570.96 | 31 |
| Allergan, Inc. | $8,574.03 | 4 |
| Mallinckrodt Hospital Products Inc. | $7,103.98 | 4 |
| Teva Pharmaceuticals USA, Inc. | $6,258.78 | 9 |
| Alexion Pharmaceuticals, Inc. | $6,151.13 | 9 |
| E.R. Squibb & Sons, L.L.C. | $6,039.36 | 19 |
| Novartis Pharmaceuticals Corporation | $2,521.81 | 28 |
| Celgene Corporation | $2,450.00 | 3 |
| Horizon Therapeutics plc | $2,421.50 | 2 |
| Merck KGaA | $1,760.00 | 1 |
| AbbVie Inc. | $1,750.00 | 1 |
| Janssen Pharmaceuticals, Inc | $1,660.00 | 1 |
| Genentech, Inc. | $1,500.00 | 1 |
| Lilly USA, LLC | $1,350.00 | 2 |
| Biohaven Pharmaceuticals, Inc. | $189.45 | 10 |
| BANNER LIFE SCIENCES, LLC | $63.55 | 3 |
| Eli Lilly Export S.A. Puerto Rico Branch | $42.48 | 3 |
| DePuy Synthes Sales Inc. | $36.77 | 1 |
| Amgen Inc. | $20.00 | 1 |
| Lundbeck LLC | $16.95 | 1 |
Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANGEL R CHINEA
NPI 1720029317 · CMS profile ID 32963
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
GUAYNABO, PR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ANGEL R CHINEA, NPI 1720029317, CMS profile ID 32963, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 300 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1720029317?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
300 matching records · $196,275.82 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 300.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EMD Serono, Inc. | $29.43 | 10/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849178043 | CMS |
| EMD Serono, Inc. | $123.22 | 10/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849183335 | CMS |
| EMD Serono, Inc. | $108.64 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849218079 | CMS |
| E.R. Squibb & Sons, L.L.C. | $79.39 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783641395 | CMS |
| BANNER LIFE SCIENCES, LLC | $22.24 | 10/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843741721 | CMS |
| EMD Serono, Inc. | $20.39 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849183927 | CMS |
| Genentech USA, Inc. | $17.60 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888545 | CMS |
| Genentech USA, Inc. | $1,800.00 | 10/19/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888573 | CMS |
| Genentech USA, Inc. | $10.68 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888575 | CMS |
| Biogen, Inc. | $19.85 | 10/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825355 | CMS |
| EMD Serono, Inc. | $120.30 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849210525 | CMS |
| Novartis Pharmaceuticals Corporation | $16.96 | 10/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812636351 | CMS |
| Biogen, Inc. | $104.20 | 10/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825335 | CMS |
| Genentech USA, Inc. | $20.52 | 10/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888525 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,128.00 | 10/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783641387 | CMS |
| GENZYME CORPORATION | $1,796.34 | 10/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485719 | CMS |
| Alexion Pharmaceuticals, Inc. | $45.88 | 10/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783114783 | CMS |
| AbbVie Inc. | $1,750.00 | 10/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794251269 | CMS |
| EMD Serono, Inc. | $117.32 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849153551 | CMS |
| EMD Serono, Inc. | $8.10 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849214269 | CMS |
| GENZYME CORPORATION | $24.53 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485687 | CMS |
| Biogen, Inc. | $2,825.00 | 10/06/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825279 | CMS |
| Biogen, Inc. | $20.93 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825333 | CMS |
| E.R. Squibb & Sons, L.L.C. | $109.04 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783641397 | CMS |
| EMD Serono, Inc. | $112.71 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849210785 | CMS |
| EMD Serono, Inc. | $3,080.00 | 10/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849150221 | CMS |
| Novartis Pharmaceuticals Corporation | $8.39 | 10/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812636401 | CMS |
| Biogen, Inc. | $24.72 | 09/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825319 | CMS |
| Genentech USA, Inc. | $11.86 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888547 | CMS |
| Teva Pharmaceuticals USA, Inc. | $139.86 | 09/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 839507603 | CMS |
| Biogen, Inc. | $15.56 | 09/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825317 | CMS |
| Alexion Pharmaceuticals, Inc. | $20.04 | 09/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783114755 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.93 | 09/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783641361 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,932.80 | 09/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783641391 | CMS |
| EMD Serono, Inc. | $3,080.00 | 09/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849148049 | CMS |
| EMD Serono, Inc. | $3,080.00 | 09/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849149441 | CMS |
| GENZYME CORPORATION | $410.23 | 09/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485709 | CMS |
| GENZYME CORPORATION | $116.14 | 09/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485711 | CMS |
| GENZYME CORPORATION | $5,962.32 | 09/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485713 | CMS |
| GENZYME CORPORATION | $373.35 | 09/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485715 | CMS |
| GENZYME CORPORATION | $561.00 | 09/17/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485717 | CMS |
| Biogen, Inc. | $1,695.00 | 09/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825263 | CMS |
| EMD Serono, Inc. | $96.38 | 09/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849210577 | CMS |
| EMD Serono, Inc. | $291.50 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849150225 | CMS |
| GENZYME CORPORATION | $23.42 | 09/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843485685 | CMS |
| Biohaven Pharmaceuticals, Inc. | $17.73 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852460101 | CMS |
| Genentech USA, Inc. | $1,800.00 | 09/14/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888569 | CMS |
| Genentech USA, Inc. | $9.96 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835888571 | CMS |
| EMD Serono, Inc. | $84.60 | 09/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849210551 | CMS |
| Biogen, Inc. | $1,695.00 | 09/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827825261 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $6,684.96 | 3 |
| PY2025 | Principal investigator | $1,907,962.24 | 33 |
| PY2024 | Principal investigator | $2,078,888.10 | 19 |
| PY2023 | Recipient | $1,351.01 | 1 |
| PY2023 | Principal investigator | $2,399,942.64 | 26 |
| PY2022 | Recipient | $6,147.00 | 5 |
| PY2022 | Principal investigator | $2,541,163.26 | 22 |
| PY2021 | Recipient | $673.00 | 2 |
| PY2021 | Principal investigator | $1,098,425.63 | 28 |
| PY2020 | Principal investigator | $432,608.52 | 30 |
| PY2019 | Recipient | $2,838.49 | 7 |
| PY2019 | Principal investigator | $1,131,727.12 | 18 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
36 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | TG Therapeutics, Inc. | $17,700.00 | 11/30/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200235 |
| Recipient | Novartis Pharmaceuticals Corporation | $509.29 | 11/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291303 |
| Principal investigator 1 | TG Therapeutics, Inc. | $24,250.00 | 11/01/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200233 |
| Principal investigator 1 | TG Therapeutics, Inc. | $5,450.00 | 09/30/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200207 |
| Principal investigator 1 | EMD Serono, Inc. | $345.00 | 09/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117939 |
| Principal investigator 1 | EMD Serono, Inc. | $978.00 | 09/22/2025 | Non-covered Recipient Entity Caribbean Center for Clinical | A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) | No dispute reported | 06/30/2026 | 1240118221 |
| Principal investigator 1 | TG Therapeutics, Inc. | $20,600.00 | 08/31/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200205 |
| Principal investigator 1 | Genentech, Inc. | $11,673.00 | 08/22/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211583833 |
| Principal investigator 1 | TG Therapeutics, Inc. | $7,525.00 | 07/31/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200203 |
| Principal investigator 1 | TG Therapeutics, Inc. | $4,198.50 | 07/31/2025 | Non-covered Recipient Entity The University of Texas at Austin | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200525 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,370.12 | 07/30/2025 | Covered Recipient Physician | COMB157GUS07 | No dispute reported | 06/30/2026 | 1190292535 |
| Principal investigator 1 | Celgene Corporation | $5,344.00 | 06/25/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research Inc | A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) | No dispute reported | 06/30/2026 | 1222306473 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $574,505.94 | 06/24/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190306921 |
| Principal investigator 1 | EMD Serono, Inc. | $20,293.00 | 06/23/2025 | Non-covered Recipient Entity Caribbean Center for Clinical | A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) | No dispute reported | 06/30/2026 | 1240118214 |
| Principal investigator 1 | Genentech, Inc. | $20,157.30 | 06/19/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211583822 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,805.55 | 06/03/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190291676 |
| Principal investigator 1 | TG Therapeutics, Inc. | $36,750.00 | 06/01/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200167 |
| Principal investigator 1 | EMD Serono, Inc. | $22,598.00 | 05/26/2025 | Non-covered Recipient Entity Caribbean Center for Clinical | A Multicenter, Observational Study to Characterize the Clinical Course in a Real-World, US Cohort of Patients with Relapsing Multiple Sclerosis of Advanced Age (>50 years) Treated with Cladribine Tablets (AGING Study) | No dispute reported | 06/30/2026 | 1240118217 |
| Principal investigator 1 | EMD Serono, Inc. | $1,345.00 | 05/22/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117943 |
| Principal investigator 1 | Genentech, Inc. | $5,947.20 | 04/17/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211583827 |
| Principal investigator 1 | TG Therapeutics, Inc. | $41,525.00 | 03/31/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200165 |
| Principal investigator 1 | EMD Serono, Inc. | $300.00 | 03/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117947 |
| Principal investigator 1 | EMD Serono, Inc. | $1,280.00 | 03/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117951 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,659.30 | 03/12/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL | Satralizumab open label treatment study in patients with NMOSD | No dispute reported | 06/30/2026 | 1211583806 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $658.75 | 03/12/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL | Satralizumab open label treatment study in patients with NMOSD | No dispute reported | 06/30/2026 | 1211583811 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $3,507.10 | 03/12/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL | Satralizumab open label treatment study in patients with NMOSD | No dispute reported | 06/30/2026 | 1211583815 |
| Principal investigator 1 | Genentech, Inc. | $2,073.60 | 03/05/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH | Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | No dispute reported | 06/30/2026 | 1211583818 |
| Principal investigator 1 | TG Therapeutics, Inc. | $52,850.00 | 02/28/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200163 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $315.88 | 02/10/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC | A phase IV, prsopective, multicenter, open-label, mother-milk study to evaluate ofatumumab concentration in the breast milk of lactating women with Relapsing forms of Multiple Sclerosis (RMS) receving kesimpta (ofatumumab) | No dispute reported | 06/30/2026 | 1190306917 |
| Principal investigator 1 | TG Therapeutics, Inc. | $1,300.00 | 02/01/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200161 |
| Principal investigator 1 | Genentech, Inc. | $7,793.00 | 01/29/2025 | Non-covered Recipient Entity CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374 | Ocrevus Subcutaneous Study for Safety and Tolerability | No dispute reported | 06/30/2026 | 1211584000 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 01/29/2025 | Non-covered Recipient Entity CARRIBEAN CENTER FOR CLINICAL RESEARCH 18374 | Ocrevus Subcutaneous Study for Safety and Tolerability | No dispute reported | 06/30/2026 | 1211584005 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,320.09 | 01/07/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190306915 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $961,629.58 | 01/06/2025 | Non-covered Recipient Entity CARIBBEAN CENTER FOR CLINICAL RESEARCH, INC | AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes | No dispute reported | 06/30/2026 | 1190306919 |
| Principal investigator 1 | TG Therapeutics, Inc. | $13,250.00 | 01/06/2025 | Non-covered Recipient Entity Caribbean Center For Clinical Research | (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | No dispute reported | 06/30/2026 | 1226200159 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $840.00 | 01/01/2025 | Non-covered Recipient Entity THE SAN JORGE HOSPITAL, INC | A two year double blind randomized multicenter active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon beta 1a i m once weekly in pediatric patients with relapsing remitting multiple scler | No dispute reported | 06/30/2026 | 1190302077 |